<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797288</url>
  </required_header>
  <id_info>
    <org_study_id>18782</org_study_id>
    <secondary_id>R01AI124214-01</secondary_id>
    <nct_id>NCT02797288</nct_id>
  </id_info>
  <brief_title>Immune Response to FMT for C.Difficile</brief_title>
  <official_title>Role of Eosinophils in Innate Protection From C. Difficile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol aims to address the basic mechanisms of Clostridium difficile pathogenesis by&#xD;
      identifying how Clostridium difficile toxins inhibit eosinophils that otherwise would protect&#xD;
      the gut from damage. This could lead to new and effective approaches to the treatment or&#xD;
      prevention of Clostridium difficile colitis that act downstream of fecal microbiota&#xD;
      transplants (FMT) or next generation probiotics. Successful fecal transplantation will&#xD;
      restore Interleukin-25, Interleukin-4 and eosinophils to the colon&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biopsies will be obtained from random areas of the sigmoid colon in subjects at the time of&#xD;
      fecal transplantation. Follow-up biopsies will be obtained from the sigmoid colon during&#xD;
      convalescence 60 days after fecal transplant for subjects who agree to return for optional 60&#xD;
      day follow-up. Biopsies taken for research purposes at each colonoscopy will be analyzed for:&#xD;
      cytokines and chemokines, gene expression analysis, immunohistochemistry and high dimensional&#xD;
      flow-cytometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>tissue IL-25</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue IL-4</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue IL-1</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue histology</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue 16s rDNA</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma metabolomics</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue eosinophils</measure>
    <time_frame>0-60 days post fecal transplant</time_frame>
    <description>single-cell atomic mass spectrometry</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Clostridium Difficile</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colon biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients receiving fecal transplant for recurrent Clostridium difficile infection&#xD;
        identified from the University of Virginia complicated Clostridium difficile clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  one or more relapse of Clostridium difficile colitis&#xD;
&#xD;
          -  eligible for fecal microbiota transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to have biopsies for research conducted at time of FMT&#xD;
&#xD;
          -  Concurrent participation in another clinical trial, except outcome of FMT study&#xD;
&#xD;
          -  Clinical contraindication to colonoscopy, FMT, flexible sigmoidoscopy or conscious&#xD;
             sedation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Incarceration&#xD;
&#xD;
          -  Antibiotics unless discontinued 48 hours prior to FMT&#xD;
&#xD;
          -  Celiac disease or any other form of inflammatory bowel disease&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Neutropenia (&lt;1000 PMNs/Âµl blood)&#xD;
&#xD;
          -  Concurrent participation in another clinical trial, except outcome of FMT study&#xD;
&#xD;
          -  Anticoagulants if not able to discontinue 5 days prior to endoscopy and flexible&#xD;
             sigmoidoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A. Petri, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William A. Petri, MD,PhD</last_name>
    <phone>434-924-5621</phone>
    <email>wap3g@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer White, BSN</last_name>
    <phone>434-982-3649</phone>
    <email>jaw9r@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William A. Petri, MD,PhD</last_name>
      <phone>434-924-5621</phone>
      <email>wap3g@virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>William Petri, MD</investigator_full_name>
    <investigator_title>Chief, Infectious Diseases &amp; International Health</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02797288/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

